The company’s manufacturing facility in Uppsala, Sweden, has been approved for manufacture of cytostatics by the Swedish Medical Products Agency.
The approval concerns manufacture for sales in the EU. With this approval, the Medical Products Agency has confirmed that Oasmia’s manufacture of cytostatics meets the requirements of current Good Manufacturing Practice (cGMP) and Oasmia now has a fully approved production facility for manufacture of cytostatics for the EU market.
”This approval is a critical step to bring our products to the market and we are very pleased that the Swedish MPA confirms Oasmia’s ability to manufacture high quality products”, said Julian Aleksov, CEO of Oasmia Pharmaceutical AB.
Advertisement
